Introduction.
The underlying hypothesis of this project was that optimal alpha emitter-based radioimmunotherapy (RAIT) could be achieved by pairing the physical half-life of the radioisotope to the biological half-life of the targeting vehicle. The project has two specific aims. The first aim was to create and optimize the therapeutic efficacy of 211 At-SAPS-C6.5 diabody conjugates. The second aim was to develop bispecific-targeting strategies that increase the specificity and efficacy of alpha-emitter-based RAIT.
Progress.
S.A.1. Dose escalation studies were performed with increasing doses of 211 AT-SAPS-C6.5 diabody specific for the HER2 tumor-associated antigen. Mice bearing established s.c. human MDA-MB-361.DYT2 breast cancer xenografts were treated with a single dose ranging from 15 to 45 µCi of 211 AT-SAPS-C6.5 diabody. In these studies, a clear dose response was observed with the greatest anti-tumor effect associated with the highest treatment dose (Figure 1 ). In the 45 µCi dose group, three of five treated animals exhibited durable complete responses, with no sign of tumor regrowth at one year following threatment (Figure 2 ). In the dose ranges studied, effective treatment was achieved a at below the acute maximum tolerated dose. All of the mice treated with 211 AT-SAPS-C6.5 diabody survived the treatment with minimal observed toxicity (minor transient weight loss). 
Tumor Age in Days
Successful RAIT depends upon specificity of effect. The impact of tumor-targeting specificity on this therapy was studied by performing RAIT using a diabody that did not target the tumor xenografts. Mice bearing established s.c. human MDA-MB-361.DYT2 breast cancer xenografts were treated with a single dose of 20 µCi of 211 At-SAPS-control diabody (a dose that caused a significant Adams, G.P.
U.S. DOE award # DE-FG02-01ER63190 Progress Report 9/03-8/04 growth delay when the anti-HER2 diabody was employed). In these studies, the mice treated with the 211 At-SAPS-control diabody displayed the same tumor growth as the untreated mice (Figure 2) , demonstrating that the anti-tumor effect observed with the anti-HER2 211 At-SAPS C6.5 diabody was specific and targeted.
As outlined in the 2003 report, we observed signs that the treatment with 211 At-SAPS C6.5 diabody may be associated with late onset renal toxicity. To examine this, we have started an ambitious project of treating large cohorts of non-tumor bearing nude mice with 20 µCi and 45 µCi of 211 At-SAPS C6.5 diabody. These mice are bled every month and samples are analyzed for signs of renal toxicity (increasing BUN and serum creatinine levels), liver toxicity (raising AST and ALT levels) and marrow toxicity (decreasing platelet counts). Every three months, cohorts of three to four treated and untreated mice are euthanized and their kidneys, livers and bone marrow are examined for signs of toxicity. We are currently 9 months past the initial treatment with 20 µCi of 211 At-SAPS C6.5 diabody and have so far found no signs of hepatic toxicity in the blood analysis or Pathology studies, however a early signs of renal toxicity were observed in these mice. This study will be continued for three more months. S.A.2. We have created ALM, an anti-HER2/anti-HER3 bispecific scFv molecule that co-targets both HER2 and HER3. Radiolabeled ALM is capable of specific localization in human tumor xenografts growing in scid mice as detected by biodistribution ( Figure  3) and ImmunoPET Imaging. As part of this grant, we have successfully demonstrated that we can specifically target ALM to tumor cells that express HER2 and HER3 in vitro in the presence of cells that only express one of the two target antigens ( Table 1) . We have also found that incubation of ALM with MCF7 cells, ZR-75 cells or BT-474 cells decreases phosphorylation of AKT, a member of the PI3-kinase signal transduction pathway that makes tumor cells less likely to undergo apoptosis in response to radiation or chemotherapy. We are currently in the process of combining this bs-scFv with radiation to see if we can achieve additive effects. 
